Dominic Störzinger

University of Münster, Muenster, North Rhine-Westphalia, Germany

Are you Dominic Störzinger?

Claim your profile

Publications (9)18.23 Total impact

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Abdominal surgery may affect intestinal absorption and the resulting levels of posaconazole in the blood. We measured plasma posaconazole levels in surgical intensive care unit (SICU) patients and tried to develop a predictive population pharmacokinetics model. A total of 270 samples from 15 patients receiving posaconazole via nasogastric tube were measured by high-performance liquid chromatography (HPLC). SICU patients showed lower plasma drug concentrations, a higher apparent clearance, and a higher volume of distribution than those in hematology patients, possibly due to poor absorption.
    Antimicrobial Agents and Chemotherapy 05/2012; 56(8):4468-70. · 4.57 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Nosocomial pneumonia is one of the most common infectious diseases acquired in hospital and is often caused by resistant pathogens. For treatment of nosocomial pneumonia an appropriate initial antibiotic therapy is essential and exact knowledge of the specific pathogen spectrum is essential for the correct choice of the empirically calculated antibiotics. In line with a critical reevaluation of the primary treatment, pathogen-specific de-escalation therapy, a diagnosis of possible pulmonary complications (e. g. pleural empyema) and the identification and appropriate rehabilitation measures of non-pulmonary infections are necessary. To attain the best possible outcome the respective therapy concept needs to be adjusted to the individual risk characteristics. Appropriate initial antibiotic therapy, duration of mechanical ventilation and comorbidities are the key factors for patient outcome. This approach helps to avoid the development of resistant pathogens and saves economic resources.
    Der Anaesthesist 03/2011; 60(3):269-81; quiz 282-3. · 0.85 Impact Factor
  • Source
    Der Anaesthesist 01/2011; 60(4):342-342. · 0.85 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The authors describe two cases of successful and safe posaconazole use in patients of a surgical intensive care unit of a university hospital.
    Mycoses 01/2011; 54 Suppl 1:45-8. · 1.28 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Considering the complexity of diagnosis, high costs of therapy and high morbidity and mortality of systemic fungal infections, antifungal therapy of intensive care patients should follow clearly defined guidelines. We outline the impact of a standardised practice of antifungal treatment in an interdisciplinary surgical intensive care unit of a university hospital. Therapy was intended to be optimised by implementation of standardised practice guidelines supported by the clinical pharmacist. Costs for antifungal agents during a period of 18 months before and after implementation of the practice guidelines were compared, respectively. The intervention was associated with a significant decrease in use of antifungal agents. Analysis of data revealed a reduction in costs by 50%. This could substantially be attributed to the implementation of the practice guidelines. The implementation of standardised practice guidelines for antifungal therapy in intensive care units decreased the use of selected antifungal agents and resulted in substantial reduction in expenditure on antifungal agents.
    Chemotherapy 12/2009; 55(6):418-24. · 2.07 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Posaconazole is a new broad-spectrum triazole antifungal drug that is used in prophylaxis and therapy of opportunistic fungal infections in immunocompromised patients. Up to now, it is available as an oral suspension only. Due to variable systemic availability known from other azoles, such as itraconazole, it is important to measure blood levels, especially in patients undergoing abdominal surgery which may influence the intestinal resorption. A sensitive and selective high-performance liquid chromatography method for the precise determination of posaconazole and the internal standard clotrimazole in human plasma was developed and validated. Samples were extracted using solid-phase extraction and separated on a reversed-phase C8 column (150 x 4.6 mm, 5 microm) using phosphate buffer (pH 6.7, 0.04 M):acetonitrile:methanol (43:49:8, v/v/v) as mobile phase. UV detection was performed at 260 nm. This method showed that a lower limit of quantification was 50 ng/mL and the limit of detection 3 ng/mL. Linearity was tested in the range from 50 to 5000 ng/mL (r(2)=0.9998). Mean recovery was 86%. The method proved to be a useful tool for therapeutic drug monitoring. It is specific, precise and showed excellent reproducibility as well as a favourable accuracy.
    Clinical Chemistry and Laboratory Medicine 11/2008; 46(12):1747-51. · 3.01 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Critically ill patients after extended surgical procedures are at high risk for postoperative infections. Fungal infections play a substantial role for immunocompromised patients, e.g. after solid organ transplantation or under chronic corticoid therapy. Posaconazole, a new broad-spectrum triazole effective against Aspergillus and Candida species as well as many fungi that are resistant to other antifungals, is well tolerated and can be used as an alternative in salvage therapy. Posaconazole can be administered via gavage so that antifungal therapy can be switched from an expensive intravenously applied antifungal to oral posaconazole at an early stage. Two case reports are presented, which show that posaconazole was efficacious and well tolerated following antifungal therapy with another azole. It was administered without difficulty via gavage to a patient receiving artificial respiration and dialysis.
    Mycoses 10/2008; 51 Suppl 2:52-7. · 1.28 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: There is concern about an increasing infiltration of markets by substandard and fake medications against life-threatening diseases in developing countries. This is particularly worrying with regard to the increasing resistance development of Plasmodium falciparum against affordable anti-malarial medications, which has led to a change to more expensive drugs in most endemic countries. A representative sample of modern anti-malarial medications from licensed (public and private pharmacies, community health workers) and illicit (market and street vendors, shops) sources has been collected in the Nouna Health District in north-western Burkina Faso in 2006. All drugs were tested for their quality with the standard procedures of the German Pharma Health Fund-Minilab. Detected low standard drugs were re-tested with European Pharmacopoeia 2.9.1 standards for disintegration and ultraviolet-visible spectroscopy at the laboratory of the Heidelberg University for confirmation. Overall, 86 anti-malarial drug samples were collected, of which 77 samples have been included in the final analysis. The sample consisted of 39/77 (50%) chloroquine, 10/77 (13%) pyrimethamine-sulphadoxine, 9/77 (12%) quinine, 6/77 (8%) amodiaquine, 9/77 (12%) artesunate, and 4/77 (5%) artemether-lumefantrine. 32/77 (42%) drug samples were found to be of poor quality, of which 28 samples failed the visual inspection, nine samples had substandard concentrations of the active ingredient, four samples showed poor disintegration, and one sample contained non of the stated active ingredient. The licensed and the illicit market contributed 5/47 (10.6%) and 27/30 (90.0%) samples of substandard drugs respectively. These findings provide further evidence for the wide-spread existence of substandard anti-malarial medications in Africa and call for strengthening of the regulatory and quality control capacity of affected countries, particularly in view of the now wider available and substantially more costly artemisinin-based combination therapies.
    Malaria Journal 02/2008; 7:95. · 3.49 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Die nosokomiale Pneumonie ist die häufigste auf Intensivstationen und nach der Harnwegsinfektion die zweithäufigste im Krankenhaus erworbene Infektionserkrankung, die nicht selten durch schwer therapierbare Erreger hervorgerufen wird. Bei der Behandlung einer nosokomialen Pneumonie steht die frühe adäquate Therapie mit einem Breitspektrumantibiotikum im Vordergrund. Dabei sind genaue Kenntnisse zum lokalspezifischen Erregerspektrum für die Auswahl der empirisch kalkulierten antiinfektiven Therapie von entscheidener Bedeutung. Im Rahmen einer kritischen Reevaluation der primären Behandlung sind eine keimspezifische Deeskalation der Therapie, die Diagnose pulmonaler Komplikationen (z.B. Pleuraempyem) und die Identifikation sowie entsprechende Sanierung möglicher nichtpulmonaler Infektionsfokusse unverzichtbar. Um einen bestmöglichen Behandlungserfolg zu erreichen, muss das jeweilige Therapiekonzept an individuellen Risikomerkmalen orientiert sein. Frühere Antibiotikagaben, Beatmungsdauer und die Komorbidität des Patienten müssen berücksichtigt werden. Dieses Vorgehen hilft, die Entwicklung von Resistenzen zu vermeiden und wirtschaftliche Resourcen zu schonen. Nosocomial pneumonia is one of the most common infectious diseases acquired in hospital and is often caused by resistant pathogens. For treatment of nosocomial pneumonia an appropriate initial antibiotic therapy is essential and exact knowledge of the specific pathogen spectrum is essential for the correct choice of the empirically calculated antibiotics. In line with a critical reevaluation of the primary treatment, pathogen-specific de-escalation therapy, a diagnosis of possible pulmonary complications (e.g. pleural empyema) and the identification and appropriate rehabilitation measures of non-pulmonary infections are necessary. To attain the best possible outcome the respective therapy concept needs to be adjusted to the individual risk characteristics. Appropriate initial antibiotic therapy, duration of mechanical ventilation and comorbidities are the key factors for patient outcome. This approach helps to avoid the development of resistant pathogens and saves economic resources. SchlüsselwörterAntibakterielle Agenzien–Verabreichung und Dosierung–Sepsis–Kreuzinfektionen–Pneumonia, ventilatorassoziiert KeywordsAntibacterial agents–Administration and dosage–Cross-infection–Sepsis–Pneumonia, ventilator-associated
    Der Anaesthesist 60(3):269-283. · 0.85 Impact Factor

Publication Stats

46 Citations
18.23 Total Impact Points

Institutions

  • 2012
    • University of Münster
      • Institute of Pharmaceutical and Medicinal Chemistry
      Muenster, North Rhine-Westphalia, Germany
  • 2008–2012
    • Universität Heidelberg
      Heidelburg, Baden-Württemberg, Germany
  • 2011
    • Universitätsklinikum Gießen und Marburg
      • Klinik für Anästhesie und Operative Intensivmedizin
      Marburg, Hesse, Germany